INO Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -31993.31% compared to Inovio Pharmaceuticals's net margin of 5.19%. Inovio Pharmaceuticals's return on equity of -98.72% beat Baxter International's return on equity of 1.33%.

Inovio Pharmaceuticals has a consensus price target of $10.67, signalling upside risk potential of 410.37%. On the other hand Baxter International has an analysts' consensus of $40.08 which suggests that it could grow by 35.47%. Given that Inovio Pharmaceuticals has higher upside potential than Baxter International, analysts believe Inovio Pharmaceuticals is more attractive than Baxter International.

Inovio Pharmaceuticals has a beta of 0.842, which suggesting that the stock is 15.846% less volatile than S&P 500. In comparison Baxter International has a beta of 0.596, suggesting its less volatile than the S&P 500 by 40.4%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3.52% to investors and pays a quarterly dividend of $0.17 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Baxter International pays out 22.06% of its earnings as a dividend. Baxter International's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Inovio Pharmaceuticals quarterly revenues are $100.8K, which are smaller than Baxter International quarterly revenues of $2.7B. Inovio Pharmaceuticals's net income of -$25.2M is lower than Baxter International's net income of $140M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Baxter International's PE ratio is 147.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 0.87x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

CervoMed has a net margin of -31993.31% compared to Inovio Pharmaceuticals's net margin of --. Inovio Pharmaceuticals's return on equity of -98.72% beat CervoMed's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $10.67, signalling upside risk potential of 410.37%. On the other hand CervoMed has an analysts' consensus of $20.00 which suggests that it could grow by 817.43%. Given that CervoMed has higher upside potential than Inovio Pharmaceuticals, analysts believe CervoMed is more attractive than Inovio Pharmaceuticals.

Inovio Pharmaceuticals has a beta of 0.842, which suggesting that the stock is 15.846% less volatile than S&P 500. In comparison CervoMed has a beta of 1.782, suggesting its more volatile than the S&P 500 by 78.196%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CervoMed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. CervoMed pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $100.8K, which are larger than CervoMed quarterly revenues of --. Inovio Pharmaceuticals's net income of -$25.2M is lower than CervoMed's net income of -$4.8M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while CervoMed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 23.47x for CervoMed. Usually stocks with elevated PS ratios are considered overvalued.

Leap Therapeutics has a net margin of -31993.31% compared to Inovio Pharmaceuticals's net margin of --. Inovio Pharmaceuticals's return on equity of -98.72% beat Leap Therapeutics's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $10.67, signalling upside risk potential of 410.37%. On the other hand Leap Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 190.5%. Given that Inovio Pharmaceuticals has higher upside potential than Leap Therapeutics, analysts believe Inovio Pharmaceuticals is more attractive than Leap Therapeutics.

Inovio Pharmaceuticals has a beta of 0.842, which suggesting that the stock is 15.846% less volatile than S&P 500. In comparison Leap Therapeutics has a beta of 0.168, suggesting its less volatile than the S&P 500 by 83.238%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Leap Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Leap Therapeutics pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $100.8K, which are larger than Leap Therapeutics quarterly revenues of --. Inovio Pharmaceuticals's net income of -$25.2M is lower than Leap Therapeutics's net income of -$18.2M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Leap Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 75.83x for Leap Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of -31993.31% compared to Inovio Pharmaceuticals's net margin of -143.53%. Inovio Pharmaceuticals's return on equity of -98.72% beat Novavax's return on equity of --.

Inovio Pharmaceuticals has a consensus price target of $10.67, signalling upside risk potential of 410.37%. On the other hand Novavax has an analysts' consensus of $16.00 which suggests that it could grow by 66.58%. Given that Inovio Pharmaceuticals has higher upside potential than Novavax, analysts believe Inovio Pharmaceuticals is more attractive than Novavax.

Inovio Pharmaceuticals has a beta of 0.842, which suggesting that the stock is 15.846% less volatile than S&P 500. In comparison Novavax has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.083%.

Inovio Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inovio Pharmaceuticals pays -- of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

Inovio Pharmaceuticals quarterly revenues are $100.8K, which are smaller than Novavax quarterly revenues of $84.5M. Inovio Pharmaceuticals's net income of -$25.2M is higher than Novavax's net income of -$121.3M. Notably, Inovio Pharmaceuticals's price-to-earnings ratio is -- while Novavax's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inovio Pharmaceuticals is -- versus 1.67x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.